Could a sleep apnea drug boost brain power in kids with down syndrome?
NCT ID NCT05933603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two medicines (atomoxetine and oxybutynin) given at bedtime for 6 months to children aged 6-17 with Down syndrome and obstructive sleep apnea. The goal is to see if the treatment improves sleep quality and thinking skills. About 36 children will take part, and their sleep and cognitive function will be measured before and after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Arizona
Tucson, Arizona, 86721, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do current sleepiness tests work for kids? a new study puts them to the test
- Remote monitoring may boost sleep apnea therapy adherence
- Could a mouthpiece replace the CPAP machine for sleep apnea?
- Can new tests unlock hidden cognitive changes in down syndrome?
- Bubble cushions may boost balance in down syndrome
- Can a new painkiller prevent breathing crises after surgery?